期刊文献+

高效表达AIM工程菌的发酵培养基及发酵条件优化 被引量:1

Optimization of Fermentation Mediums and Fermentation Conditions for AIM Production by Engineering Bacteria
下载PDF
导出
摘要 为了进一步提高工程菌的载脂蛋白AI米兰突变体(AIM)的表达量,降低发酵成本,通过碳氮源优化实验并结合正交实验筛选出该工程菌产AIM的最适培养基为(g/L):蔗糖10,酵母粉10,硫酸铵6和NaCl 10;最适发酵条件为:装液量30 mL,接种量8%,诱导时机A600 1.0,诱导剂浓度0.8 mmol/L,诱导时间6 h.在此优化的条件下,AIM的表达量为2.26 g/L,是未优化条件下的1.58倍. The optimal medium and optimal fermentation condition for AIM production by engineering bacteria were founded through carbon and nitrogen sources optimization experiments and orthogonal experiments. The optimal medium (g/L) :sucrose 10,yeast powder 10, ammonium sulfate 6 and NaCl 10. The optimal fermentation condition :liquid loading 30 mL,inoculum size 8%,induction opportunity A600 1.0,inductor concentration 0.8 mmol/L,induction time 6 h. Expression level of AIM is 2.26 g/L in the optimized conditions, which is the 1.58 times of the expression level in the basic conditions.
出处 《天津科技大学学报》 CAS 2010年第3期9-13,共5页 Journal of Tianjin University of Science & Technology
关键词 载脂蛋白AI米兰突变体 发酵培养基 发酵条件 大肠杆菌 apolipoprotein A-I-Milano fermentation media fermentation conditions E.coli
  • 相关文献

参考文献10

  • 1Sedlis S P,Schechtman K B,Ludbrook P A,et al.Plasma apoproteins and the severity of coronary artery disease[J].Circulation,1986,73 (5):978-986.
  • 2Paszty C,Maeda N,Verstuyft J,et al.Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice[J].J Clin Invest,1994,94(2):899-903.
  • 3Fruchart J,CDuriez P.High density lipoprotein and coronary heart disease.Future prospects in gene therapy[J].Biochimie,1998,80 (2):167-172.
  • 4Gualandri V,Franceschini G,Sirtori C R,et al.AIMilano apoprotein indentification of the complete kindred and evidence of a dominant genetic transmission[J].Am J Hum Genet,1985,37(6):1083-1097.
  • 5Calabresi L,Franceschini G,Burkybile A,et al.Activtion of lecithin-cholesterol acyltransferase by a disulfide bridge remarkably alters apolipoprotein A-I dimmer[J].Biochem Biophys Res Commun,1997,232:345-349.
  • 6Calabresi L,Franceschini G,Sirtori C R,et al.Inhibition of VCAM-1 expresson in endothelial cells by reconstituted high density lipoproteins[J].Biochem Biophys Res Commun,1997,238(1):61-65.
  • 7Bielicki J K,Oda M N.Apolipoprotein A-I(Milano)and apolipoprotein A-I (paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I[J].Biochemistry,2002,41 (6):2089-2096.
  • 8Calabresi L,Vecchio G,Longhi R,et al.Molecular characterization of native and recombinant apolipoprotein A-I Milano dimmer[J].J Biol Chem,1994,269(51):32168-32174.
  • 9Shah P K,Yano J,Reyes O,et al.High-dose recombinant apolipoprotein A-I (milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice.Potential implications for acute plaque stabilization[J].Circulation,2001,103(25):3047-3050.
  • 10马文峰,丁满生,郭美锦,庄英萍,储炬,张嗣良.重组人载脂蛋白ApoA-I表达条件的优化[J].微生物学通报,2004,31(6):27-32. 被引量:2

二级参考文献7

  • 1Rubin E M, Krauss R M, Spangler E A, et al . Nature, 1991, 353 (6341): 265-267.
  • 2Hartmut H J, Schmidt R E.Clinica Chimica Acta, 1997, 268 (1-2): 41-60.
  • 3Hartmut H J, Schmidt J G.Prot Exp Purif, 1997, 10 (2): 226-236.
  • 4Liu A C, Lawn R M, Verstuyft J G et al. J Lipid Res, 1994, 35 (12): 2263-2267.
  • 5Sanjoy K B , Ashok K D.Biotechnol Prog, 1997, 13:151 - 155.
  • 6Han K, Lim H C, Hong J.Biotechnol Bioeng, 1992, 39: 663-671.
  • 7Joyce D.Appl Biochem and Biotechn, 1993, 39/40:301 - 322.

共引文献1

同被引文献12

  • 1张彩,王郡甫,刘金生,许晓群,张建华,张捷,冯进波,田志刚.重组人白细胞介素15工程菌高密度发酵条件探讨[J].中国生化药物杂志,2007,28(1):1-3. 被引量:8
  • 2Jones D S, Silverman A P, Cochran J R. Developing therapeutic proteins by engineering ligand-receptor interactions [ J ]. Trends Biotechnol,2008,26(9) :498.
  • 3Bemelans M H A, Van Tits L J, Buurman W A. Tumor necrosis factor; function,release and clearance[ J] . Crit Reviews Immunol, 1996,16:1.
  • 4Deng GM,Zheng LX,Francis Chan K M,ef al. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors [ J ]. Nat Med,2005,11 (10) :1066.
  • 5Deng GM, Liu I, Tsokos G C. Inhibition of TNFR1 signaling by P60 PLAD protein ameliorates skin lesions in lupus MRL/lpr mice[ J]. J Immuno,2009,182 :50. 24.
  • 6Wong M, Ziring D,Korin Y, et al. TNFa blockade in humandiseases : Mechanisms and future directions [ J ]. Clin Immunol, 2008,126:121.
  • 7Francis Chan K M. The pre-ligand binding assembly domain : a potential target of inhibition of tumour necrosis factor receptor function[ J]. Ann Rheum Dis,2000,59( suppl I) :i50.
  • 8沈同,王镜岩.生物化学(下册)[M].北京:髙等教育出版社,二版,2000,30.
  • 9巴特,刘承初,杨旦,谢晶,李应森,李家乐.乳铁蛋白肽基因工程菌(E.col-ipED-LfcinB BL21)的发酵与诱导表达条件优化[J].辽宁农业科学,2010(5):21-27. 被引量:1
  • 10杨涛,杨利军,张建林,张悦红,牛勃.抗TNFα单链抗体在大肠杆菌中可溶性表达条件的研究[J].药物生物技术,2010,17(6):482-486. 被引量:8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部